ZenenCell 'Premensia', Approved as an Individually Recognized Functional Ingredient for Premenstrual Syndrome Improvement

Genensel announced on the 17th that its self-developed natural material "Malt and Gujeolcho Extract Complex (ingredient name: Frimensia)" has obtained individual recognition as a functional ingredient for improving premenstrual syndrome (PMS) in women from the Ministry of Food and Drug Safety.

Jenesel Logo
Photo by Jenesel

Since 2017, Genensel has invested about 3 billion KRW over six years to successfully develop "Frimensia" through joint research with Professor Kang Se-chan's team at Kyung Hee University and Dongkook Pharmaceutical. This time, the Ministry of Food and Drug Safety recognized its functionality with the statement that it "may help improve uncomfortable conditions caused by premenstrual changes." Individual recognition-type functional ingredients are materials not listed or registered in official notifications, which companies independently research and prove through experiments that they benefit health, and then receive approval from the Ministry of Food and Drug Safety. Although the recognition criteria are stringent, including functionality, safety, manufacturing methods, standards, and intake verification, once approved, the company can hold exclusive manufacturing and sales rights for a certain period.

Genensel explained that through preclinical and human application trials, Frimensia was proven to normalize prolactin (milk hormone) secretion by activating dopamine receptors and inhibit estrogen (female hormone) receptor activation. Additionally, it confirmed effects such as alleviating PMS symptoms, protecting pituitary cells, and improving uterine inflammation.

PMS is a condition experienced by more than one-third of women of reproductive age, presenting symptoms such as mild mental disorders, abdominal bloating, weight gain, breast tenderness, muscle tension, decreased concentration, and appetite changes. These symptoms can cause difficulties in workplace life and reduce women's social activities. Despite ongoing efforts to address this, there are few appropriate treatments, and antidepressants, anti-inflammatory analgesics, and oral contraceptives are mainly prescribed.

A Genensel representative stated, "Since PMS requires long-term management, consumer demand for health functional foods with excellent efficacy and minimal side effects is continuously increasing," adding, "We expect positive market response as we develop safe, high-functional ingredients using domestic native plants." Genensel has completed domestic patent registration for Frimensia and has filed patents in nine overseas regions including the United States, Europe, Australia, and Japan.

This content was produced with the assistance of AI translation services.